NeoStem's Progenitor Cell Therapy Enters Deal for Cell Therapy Manufacturing Services
NeoStem, Inc. (NYSE: NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1^c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.